Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531

ArQule, Inc. (Nasdaq:ARQL) today is presenting preliminary results from the Company's Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor of...

ARQL : 4.99 (-6.03%)
ArQule to Present at The JMP Securities Life Sciences Conference on June 21, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at...

ARQL : 4.99 (-6.03%)
Options Traders Expect Huge Moves in ArQule (ARQL) Stock

ArQule (ARQL) needs investors to pay close attention to the stock based on moves in the options market lately.

ARQL : 4.99 (-6.03%)
The Race to Treat Cancer, ArQule Inc. Continues Progress Across All Pipeline Assets

Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on ArQule Inc. (NASDAQ: ARQL), a bio-pharmaceutical...

ARQL : 4.99 (-6.03%)
Research Report Identifies Qudian Inc., ICICI Bank, Mobile TeleSystems OJSC, ArQule, Alibaba Group Holding, and Arcos Dorados with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Qudian Inc. (NYSE:QD), ICICI...

BABA : 208.00 (-1.36%)
ARQL : 4.99 (-6.03%)
QD : 9.44 (+1.72%)
ARCO : 7.40 (+3.50%)
IBN : 8.28 (-1.31%)
MBT : 9.21 (-0.86%)
ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 23rd Congress of the European Hematology Association (EHA)

ArQule, Inc. (Nasdaq: ARQL) today announced clinical data from the company-sponsored ARQ 531-101 Phase 1 dose escalation study in subjects with relapsed or refractory hematologic malignancies...

ARQL : 4.99 (-6.03%)
ArQule to Present at the Jefferies 2018 Healthcare Conference on June 7, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at...

ARQL : 4.99 (-6.03%)
ArQule Strengthens Executive Team with Two Key Appointments

ArQule, Inc. (NASDAQ: ARQL) today announced two strategic additions to its executive team, appointing Dr. Marc Schegerin as senior vice president, corporate strategy, communication and finance,...

ARQL : 4.99 (-6.03%)
What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?

Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.

ARQL : 4.99 (-6.03%)
SMMT : 12.56 (-0.40%)
PFE : 36.36 (+0.55%)
MKGAF : 97.9250 (+0.80%)
ArQule Reports First Quarter 2018 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the first quarter of 2018.

ARQL : 4.99 (-6.03%)
ArQule, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 7, 2018 / ArQule, Inc. (NASDAQ: ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 7, 2018 at 9:00 AM Eastern Time.

ARQL : 4.99 (-6.03%)
ArQule to Report First Quarter 2018 Financial Results on May 7, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the first quarter of 2018 before the market opens on Monday, May 7, 2018. The Company will hold a conference...

ARQL : 4.99 (-6.03%)
Basilea licenses late-stage oncology drug candidate derazantinib from ArQule

Basilea Pharmaceutica AG / Basilea licenses late-stage oncology drug candidate derazantinib from ArQule . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the...

ARQL : 4.99 (-6.03%)
Will ArQule (ARQL) Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in ArQule, Inc. (ARQL)

ARQL : 4.99 (-6.03%)
Recent Analysis Shows Energy Fuels, Vipshop, Tenaris S.A, ArQule, Teekay Offshore Partners, and Chicago Bridge & Iron Company N.V Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Energy Fuels Inc (NYSE:UUUU),...

ARQL : 4.99 (-6.03%)
TOO : 2.49 (-3.86%)
UUUU : 2.02 (-0.98%)
CBI : 16.39 (+1.67%)
VIPS : 11.23 (+1.08%)
TS : 35.42 (-3.54%)
ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at...

ARQL : 4.99 (-6.03%)
ArQule (ARQL) in Focus: Stock Moves 15.6% Higher

Shares of ArQule (ARQL) rose nearly 16% yesterday.

ARQL : 4.99 (-6.03%)
ENTA : 115.33 (+3.90%)
ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that pre-clinical and clinical data on the company's pipeline of drug candidates will be presented at the 2018 AACR Annual Meeting taking place...

ARQL : 4.99 (-6.03%)
ArQule, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 5, 2018 / ArQule, Inc. (NASDAQ: ARQL) will be discussing their earnings results in their Q4 Earnings Call to be held on March 5, 2018, at 9:00 AM Eastern Time.

ARQL : 4.99 (-6.03%)
ArQule Reports Fourth Quarter and Full Year 2017 Financial Results

ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the fourth quarter and full year of 2017.

ARQL : 4.99 (-6.03%)

Van Meerten Stock Picks

5 Great Large Caps
This morning I wanted to find 5 Large Cap stocks that had performed well over the last year and still appeared to have some juice left in them.
ABMD +2.93 , NFLX -0.89 , VLO -1.64 , RL +0.62 , ALGN -3.61
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures closed with most nearby contracts 1 to 2 cents lower on Friday, despite showing gains at midday. Front month July lost 4.37% on the week. December fell to within 1 1/4 cents of the life of contract low in the overnight session. Managed m...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar